Treatment progress of mantle cell lymphoma

VernacularTitle:套细胞淋巴瘤治疗进展
Author: Mingkun KOU ¹ ; Tao WU ; Nana XU ; Shunyu LIANG ; Hai BAI
Author Information

1. 解放军联勤保障部队第九四〇医院全军血液病中心，兰州　730050
Keywords: Lymphoma, mantle-cell; Hematopoietic stem cell transplantation; Immunotherapy; Antineoplastic combined chemotherapy protocols
From: Journal of Leukemia & Lymphoma 2021;30(9):572-576
CountryChina
Language:Chinese
Abstract: Mantle cell lymphoma is a B-cell malignancy with unique biological, pathological and clinical characteristics, accounting for about 5%-10% of non-Hodgkin lymphoma (NHL), and most patients are diagnosed at advanced stage. Mantle cell lymphoma has the aggressive characteristic of aggressive lymphoma and the refractory characteristic of indolent lymphoma, and the prognosis of patients is poor. In recent years, with the development of high-dose chemotherapy, autologous hematopoietic stem cell transplantation and new drug research, the survival time of patients has been significantly prolonged.